Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
System-State: Number of processed items 16.108 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US7170811035
State: 18.11.2024 | 6PM
Do you already know our new terminal view? Click here.
FIGI: BBG000BR2B91
PFE
Pfizer Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Drug Manufacturers - General
NAME
Pfizer Inc.
ISIN
US7170811035
TICKER
PFE
MIC
XNYS
REUTERS
PFE.N
BLOOMBERG
PFE US
Thu, 14.11.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Andrew Baum, Chief Strategy and Innovation Officer, Executive Vice President, and Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 9:00...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Aamir Malik, Chief U.S. Commercial Officer, Executive Vice President, at the UBS Global Healthcare Conference on Wednesday, November 13, 2024 at 12:30 p.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.c...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Tue, 29.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance(1) for both Revenues and Adjusted(2) diluted EPS. The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pf...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Wed, 23.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal vaccines, including PREVNAR 20® (20-valent Pneumococcal Conjugate Vaccine) for all adults aged 50 and older. This recommen...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Tue, 22.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age who are at increased ris...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer (“Tim”) J. Buckley to its Board of Directors, effective immediately, following a lengthy and comprehensive search that began in May 2024. Mr. Buckley, age 55, was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer’s Board. Fo...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Fri, 11.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVII...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in patients with metastatic ca...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.42 fourth-quarter 2024 dividend on the company’s common stock, payable December 2, 2024, to holders of the Common Stock of record at the close of business on November 8, 2024. The fourth-quarter 2024 cash dividend will be the 344th consecutive quarterly dividend paid...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2024 congress, held in Los Angeles from October 16-19, 2024. Data in 49 abstracts from company- and collaborator-led studies, will highlight the advances Pfizer is making in helping prevent and treat infectious diseases. “Pfizer is at the fore...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Wed, 25.09.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the to...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Fri, 20.09.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to p...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Tue, 17.09.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, October 29, 2024. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2024 Performance Report, to be issued that mo...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Sat, 14.09.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting ...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Sat, 14.09.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After an additional 18 months of follow-u...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Wed, 11.09.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17 in Barcelona. Data from more than 50 company-sponsored, investigator-sponsored and collaborative researc...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Wed, 28.08.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 8:30 a.m. EDT. To view and listen to the webcast, visit our web si...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Tue, 27.08.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE) today introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S. The new, end-to-end experience will support the millions of Americans affected annually by common illnesses like migraine, COVID-19 or flu, and those...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Thu, 22.08.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the supplemental Biologics License Application for individuals 12 years of age and older (COMIRNATY® (COVID-19 Vaccine, mRNA), and granted emergency use authorization for individuals 6 months ...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink
Fri, 16.08.2024       Pfizer
US7170811035

Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The combination candidate consists of Pfizer’s mRNA-based influenza vacc...
Read More
Pfizer
Technical Analysis Termsheet Terminal
Permalink

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.